<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04968015</url>
  </required_header>
  <id_info>
    <org_study_id>LAMSA2020</org_study_id>
    <nct_id>NCT04968015</nct_id>
  </id_info>
  <brief_title>Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission</brief_title>
  <acronym>LAMSA2020</acronym>
  <official_title>A Phase II Randomized Study to Assess the Efficacy on Outcome of Venetoclax Combined With Cytarabine Versus Idarubicin Combined With Cytarabine Administered as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For the FILO group, the standard of care for induction chemotherapy of elderly fit patients&#xD;
      with AML is represented by the combination of Cytarabine, Idarubicin and Lomustine. The&#xD;
      superiority of this combination was confirmed in a larger prospective study the LAMSA-2007.&#xD;
      This induction treatment, followed by six courses of consolidation (Idarubicin and&#xD;
      Cytarabine) followed then by a period of 6-month maintenance therapy, allows up to 80 % of&#xD;
      remission, and a RFS of 46 % at 2 years.&#xD;
&#xD;
      The aim of the study is to assess the efficacy on outcome of Venetoclax combined with&#xD;
      Cytarabine versus Idarubicin combined with Cytarabine administered as post-remission therapy&#xD;
      to elderly patients with acute myeloid leukemia in first complete remission (CR) following&#xD;
      induction chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute myeloid leukemia is characterized by the clonal expansion of myeloid blasts in the bone&#xD;
      marrow, peripheral blood and extramedullary tissues which disrupts normal hematopoiesis.&#xD;
&#xD;
      It is the most common form of acute leukemia in adults with an estimated 19,950 new cases and&#xD;
      10,430 deaths in 2016 in the United States. The prevalence is approximately 36,000 in the US&#xD;
      alone. The median age of diagnosis is 67 years, with 55 % of the patients diagnosed at 65&#xD;
      years or older, and approximately a third of them are diagnosed over the age of 75.&#xD;
&#xD;
      Due to a higher frequency of poor prognosis factors such as adverse cytogenetics, previous&#xD;
      history of myelodysplastic syndrome (MDS) or therapy-related AML (t-AML), the prognosis of&#xD;
      elderly AML remains dismal in patients &gt; 60 years.&#xD;
&#xD;
      The complete remission rate achieved after induction chemotherapy is lower than in young&#xD;
      adults, and the remission duration is seldom longer than a year. Consequently, the overall&#xD;
      survival of these patients rarely excesses 10-15 % beyond 5 years from diagnosis. For this&#xD;
      group of patients, improving the efficacy of post induction chemotherapy and preventing&#xD;
      relapse, without increasing the treatment-related mortality, remain a challenge.&#xD;
&#xD;
      For the FILO group, the standard of care for induction chemotherapy of elderly fit patients&#xD;
      with AML is represented by the combination of Cytarabine, Idarubicin and Lomustine (ICL:&#xD;
      Idarubicin 8 mg per square meter per day, IV on days 1-5, Cytarabine 100 mg per square meter&#xD;
      per day on days 1-7 IV continuously, Lomustine 200 mg per square meter orally at day 1). This&#xD;
      induction treatment, followed by six courses of consolidation, consisting of reduced doses of&#xD;
      Idarubicin 8 mg per square meter per day IV on day 1 and Cytarabine 50 mg per square&#xD;
      meter/12h/d subcutaneously on days 1-5 followed then by a period of 6-month maintenance&#xD;
      therapy, allows up to 80 % of remission, an improvement in 2-year Event Free Survival from 26&#xD;
      % to 41 %, and a 2 year relapse free survival improvement from of 33 % to 46 % for patients&#xD;
      without unfavorable cytogenetics.&#xD;
&#xD;
      Venetoclax is a potent, selective and orally bioavailable small molecule inhibitor of BCL-2&#xD;
      (B-cell lymphoma 2), an anti-apoptotic protein which overexpression is associated with tumor&#xD;
      initiation, disease progression, and drug resistance, and is thus a compelling target for&#xD;
      anti-tumor therapy. Phse I/II studies have assessed venetoclax as single agent or in&#xD;
      combination with low dose Cytarabine (LDAC) in upfront treatment of AML patients aged ≥ 65&#xD;
      years old and not eligible for standard Cytarabine and anthracycline-based induction therapy&#xD;
      with encouraging results. The aim of the study is to assess the efficacy on outcome of&#xD;
      Venetoclax combined with Cytarabine versus Idarubicin combined with Cytarabine administered&#xD;
      as post-remission therapy to elderly patients with acute myeloid leukemia in first complete&#xD;
      remission (CR) following induction chemotherapy.&#xD;
&#xD;
      Subjects will be randomized 1:1 to receive Venetoclax or Idarubicin associated to Cytarabine&#xD;
      for 6 cycles x 28 days. Patients will be followed until progression or death or until the end&#xD;
      of study defined by the number of relapse-free survival (RFS) events and last patient&#xD;
      treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2028</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase II open label controlled study. Subjects will be randomized 1:1 to receive Venetoclax or Idarubicin associated to Cytarabine</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse Free Survival (RFS)</measure>
    <time_frame>from randomization to last follow-up (up to 5 years)</time_frame>
    <description>RFS measured from the date of achievement of a remission until the date of relapse or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 2 years</measure>
    <time_frame>from date of randomization to 2 years after last administration of experimental treatment</time_frame>
    <description>time from date of randomization to date of death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>VEN-CYTA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax 600mg/day, Per Os (PO), D1 to D14 / 28 days cycle Cytarabine 50 mg/m2/12h Subcutaneous (SC), D1 to D5 / 28 days cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDA-CYTA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Idarubicin 8mg/m2, Intravenous (IV), at D1 / 28 days cycle Cytarabine 50 mg/m2/12h, SC, D1 to D5 / 28 days cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine-Venetoclax Association</intervention_name>
    <description>Consolidation treatment with cytarabine + venetoclax</description>
    <arm_group_label>VEN-CYTA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine-Idarubicin Association</intervention_name>
    <description>Consolidation treatment with cytarabine + idarubicin</description>
    <arm_group_label>IDA-CYTA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  ≥ 60 years of age.&#xD;
&#xD;
          -  AML de novo according to the WHO 2016 classification&#xD;
&#xD;
          -  AML with favorable or intermediate cytogenetics according to ELN 2017&#xD;
&#xD;
          -  Subjects should be eligible for intensive chemotherapy by Idarubicin, Cytarabine, and&#xD;
             Lomustine (standard induction for FILO)&#xD;
&#xD;
          -  SORROR &lt; 3 (for the protocol, calculation of Sorror excludes a history of cancer)&#xD;
             (appendix 2)&#xD;
&#xD;
          -  AML secondary to MDS or chemotherapy are eligible, unless adverse cytogenetics&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) &lt; 3 (appendix 1)&#xD;
&#xD;
          -  Adequate baseline organ function defined by the criteria below:&#xD;
&#xD;
               -  Adequate renal function as demonstrated by a creatinine clearance ≥ 50 mL/min;&#xD;
                  calculated by the Cockcroft Gault formula or measured by 24-hours urine&#xD;
                  collection&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) ≤ 3.0 × upper limit of normal (ULN)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) ≤ 3.0 × ULN&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 × ULN&#xD;
&#xD;
          -  Adequate cardiac function with Left Ventricular Ejection Fraction (LVEF) ≥ 50 %&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical conditions&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  Females must be menopausal to be pre-enrolled&#xD;
&#xD;
          -  Patients must be affiliated to the French Social Security (health insurance)&#xD;
&#xD;
          -  Signed written informed consent for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Acute Promyelocytic Leukemia (APL)&#xD;
&#xD;
          -  AML with adverse cytogenetics according to ELN 2017&#xD;
&#xD;
          -  AML with BCR-ABL1 translocation&#xD;
&#xD;
          -  Subject with an antecedent of myeloproliferative neoplasm (MPN) including&#xD;
             myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous&#xD;
             leukemia (CML) with or without BCR-ABL1 translocation&#xD;
&#xD;
          -  Clinical symptoms suggesting active central nervous system leukemia, or presence of&#xD;
             isolated extramedullary leukemia&#xD;
&#xD;
          -  Previous exposure of anthracycline ≥ 550 mg/m² (Daunorubicin equivalence)&#xD;
&#xD;
          -  Previous AML treatment other than Hydroxyurea&#xD;
&#xD;
          -  Treatment with an investigational drug within 30 days or 5 half-life whichever is&#xD;
             longer, preceding the initiation study and/or previous treatment with Venetoclax&#xD;
&#xD;
          -  History of another malignancy within the past 3 years except basal cell carcinoma of&#xD;
             the skin or cervix in situ carcinoma&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormalities or psychiatric illness that&#xD;
             would place the participant at an unacceptable risk or prevent them from giving&#xD;
             informed consent or precluding the administration of protocol treatments&#xD;
&#xD;
          -  Other comorbidity that the physician judges to be incompatible with conventional&#xD;
             intensive chemotherapy which must be reviewed and approved by the study medical&#xD;
             monitor before study enrolment&#xD;
&#xD;
          -  Subject with known HIV infection (due to potential drug-drug interactions between&#xD;
             antiretroviral medications and Venetoclax). HIV testing will be performed at&#xD;
             Screening. Subject known to be positive for hepatitis B virus (HBV) or hepatitis C&#xD;
             virus (HCV) infection. Inactive hepatitis carrier status with undetectable Polymerase&#xD;
             Chain Reaction (PCR) viral load on antivirals (non-exclusionary medications) are not&#xD;
             excluded.&#xD;
&#xD;
        Randomization criteria:&#xD;
&#xD;
          1. Subjects must have been registered at diagnosis&#xD;
&#xD;
          2. Subjects must have received intensive induction by Idarubicin, Cytarabine and&#xD;
             Lomustine&#xD;
&#xD;
          3. Patients in Complete Response / Complete Response with incomplete hematologic recovery&#xD;
             (CR/CRi) post induction according to ELN 2017 criteria&#xD;
&#xD;
          4. Randomization should be performed no more than D+60 after induction&#xD;
&#xD;
          5. ECOG &lt; 3 (appendix 1)&#xD;
&#xD;
          6. Adequate baseline organ function defined by the criteria below:&#xD;
&#xD;
               -  Adequate renal function as demonstrated by a creatinine clearance ≥ 50 mL/min;&#xD;
                  calculated by the Cockcroft Gault formula or measured by 24-hours urine&#xD;
                  collection&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) ≤ 3.0 × ULN&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) ≤ 3.0 × ULN&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 × ULN&#xD;
&#xD;
          7. Adequate cardiac function with LVEF ≥ 50 %&#xD;
&#xD;
          8. Male subjects who are sexually active must agree, from study Day 1 through at least&#xD;
             180 days after the last dose of study drug, to practice protocol-specified methods of&#xD;
             contraception&#xD;
&#xD;
          9. Female subjects must be postmenopausal defined as with no menses for 12 or more months&#xD;
             without an alternative medical cause&#xD;
&#xD;
        Non randomization criteria&#xD;
&#xD;
          1. Patient in Partial Remission (PR) or failure following one induction course by&#xD;
             Idarubicin, Cytarabine and Lomustine (according ELN 2017 criteria)&#xD;
&#xD;
          2. Uncontrolled infection&#xD;
&#xD;
          3. Subject with cardiovascular disability status as per New York Heart Association Class&#xD;
             &gt; 2. Class 2 is defined as cardiac disease in which subjects are comfortable at rest&#xD;
             but ordinary physical activity results in fatigue, palpitations, dyspnea, or angina&#xD;
             pain. Class 3 is defined as cardiac disease in which subjects are comfortable at rest&#xD;
             but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class 4 is&#xD;
             defined as cardiac disease in which subjects have an inability to carry on any&#xD;
             physical activity without discomfort, symptoms of heart failure at rest, and if any&#xD;
             physical activity is undertaken then discomfort increases.&#xD;
&#xD;
          4. Subject has a malabsorption syndrome or other condition that precludes enteral route&#xD;
             of administration.&#xD;
&#xD;
          5. Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would place the participant at an unacceptable risk or prevent them from giving&#xD;
             informed consent.&#xD;
&#xD;
          6. Treatment with any of the following within 7 days prior to the first dose of study&#xD;
             drug :&#xD;
&#xD;
               -  Strong or moderate CYP3A inducers&#xD;
&#xD;
               -  Steroid therapy for anti-neoplastic intent&#xD;
&#xD;
          7. Subject having consumed grapefruit, grapefruit products, Seville oranges (including&#xD;
             marmalade containing Seville oranges) or Star fruit within 3 days prior to the&#xD;
             initiation of study treatment.&#xD;
&#xD;
          8. Subject having chronic respiratory disease that requires continuous oxygen, or a&#xD;
             significant history of renal, neurologic, psychiatric, endocrinologic, metabolic,&#xD;
             immunologic, hepatic, cardiovascular disease, any other medical condition that in the&#xD;
             opinion of the investigator would adversely affect his/her participating in this&#xD;
             study.&#xD;
&#xD;
          9. Previous treatment with Venetoclax and/or current participation in any other research&#xD;
             study with investigational products.&#xD;
&#xD;
         10. Known hypersensitivity to the study medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud PIGNEUX, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>FILO (French Innovative Leukemia Organization)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ariane MINEUR</last_name>
    <phone>05 57 62 31 08</phone>
    <phone_ext>+33</phone_ext>
    <email>ariane.mineur@filo-leucemie.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>ANGERS - CHU - Maladies du sang</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathilde HUNAULT, Dr</last_name>
      <phone>02 41 35 45 82</phone>
      <email>mahunault@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ANNECY - Centre Hospitalier Annecy-Genevois</name>
      <address>
        <city>Annecy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Frédérique ORSINI-PIOCELLE, MD</last_name>
      <email>forsinipiocelle@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AVIGNON - Centre Hospitalier</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAYONNE - CH de la Côte Basque - Hématologie</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne BANOS, Dr</last_name>
      <phone>+33 5 59 44 38 32</phone>
      <email>abanos@ch-cotebasque.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BESANCON - Hôpital Jean Minjoz - Hématologie</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Yohan DESBROSSES, Dr</last_name>
      <phone>+33 3 81 66 82 32</phone>
      <email>ydesbrosses@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BEZIERS - Centre Hospitalier - Hématologie</name>
      <address>
        <city>Béziers</city>
        <zip>34500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alain SAAD, Dr</last_name>
      <phone>+33 4 67 35 70 63</phone>
      <email>alain.saad@ch-beziers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand - Chu Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Romain Guieze, MD</last_name>
      <phone>+33473750766</phone>
      <email>rguieze@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grenoble - CHUGA - Hématologie Clinique</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Martin CARRE, Dr</last_name>
      <phone>+33 4 76 76 57 55</phone>
      <email>mcarre1@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LYON-Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Amine BELHABRI, MD</last_name>
      <email>amine.belhabri@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MARSEILLE - Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Yosr HICHERi, Dr</last_name>
      <email>HICHERIY@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>METZ - CHR Metz-Thionville</name>
      <address>
        <city>Metz</city>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Houria DEBARRI, MD</last_name>
      <email>h.debarri@chr-metz-thionville.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MONTPELLIER - Hôpital Saint-Eloi - Hématologie Clinique</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eve GEHLKOPF, Dr</last_name>
      <email>e-gehlkopf@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MULHOUSE - Hôpital E. Muller - Hématologie</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mario OJEDA-URIBE, Dr</last_name>
      <phone>+33(0)3 89 64 77 55</phone>
      <email>ojeda-uribem@ghrmsa.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NANTES - Hôpital Hôtel Dieu - Hématologie Clinique</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre PETERLIN, Dr</last_name>
      <phone>+33(0)2 40 08 32 71</phone>
      <email>pierre.peterlin@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NIMES - CHU Caremeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric JOURDAN, Dr</last_name>
      <phone>04 66 68 32 31</phone>
      <email>eric.jourdan@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ORLEANS - CHR - Hématologie</name>
      <address>
        <city>Orléans</city>
        <zip>44100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marlene OCHMANN, Dr</last_name>
      <email>marlene.ochmann@chr-orleans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PERPIGNAN - CH St Jean - Hématologie Clinique</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandra KARANGWA, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BORDEAUX - Hôpital Haut-Levêque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Arnaud PIGNEUX, Pr</last_name>
      <email>arnaud.pigneux@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>POITIERS - Hôpital La Milétrie - Hématologie Clinique</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria-Pilar GALLEGO-HERNANZ, Dr</last_name>
      <phone>+33(0)5 49 44 44 44</phone>
      <email>maria-pilar.gallego-hernanz@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>REIMS - Hôpital Robert Debré - Hématologie Clinique</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Chantal HIMBERLIN, Dr</last_name>
      <phone>+33(0)3 26 78 36 44</phone>
      <email>chimberlin@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RENNES - Hôpital Pontchaillou - Hématologie</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc BERNARD, Dr</last_name>
      <phone>+33(0)2 99 28 99 86</phone>
      <email>marc.bernard@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ST ETIENNE - Institut De Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuelle TAVERNIER</last_name>
      <email>emmanuelle.tavernier@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Strasbourg - Icans</name>
      <address>
        <city>Strasbourg</city>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Célestine SIMAND, MD</last_name>
      <email>c.simand@icans.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toulouse - IUCT Oncopole - Service d'Hématologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian RECHER, Pr</last_name>
      <phone>+33 5 31 15 63 55</phone>
      <email>recher.christian@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TOURS - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alban VILLATE, MD</last_name>
      <email>a.villate@chu-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NANCY - CHU de Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gabrielle ROTH-GUEPIN, Dr</last_name>
      <email>g.roth-guepin@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

